Lymphocyte Subpopulations, Oxidative Burst and Apoptosis in Peripheral Blood Cells of Patients with Multiple Sclerosis-Effect of Interferon

At present, the most efficient therapeutical treatment of multiple sclerosis (MS) is achieved by IFN- . However, its in vivo effects remain incompletely understood. If applied parenterally, the hydrophobic IFN- acts primarily on blood cells with probable selectivity for functionally different lympho...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Autoimmunity (Chur, Switzerland) Switzerland), 2003-08, Vol.36 (5), p.291-305
Hauptverfasser: Mix, Eilhard, Stefan, Katja, Höppner, Jaqueline, Klauer, Thomas, Zettl, Uwe K., Strauss, Ulf, Meyer-Rienecker, Hans-J., Rolfs, Arndt
Format: Artikel
Sprache:eng
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 305
container_issue 5
container_start_page 291
container_title Autoimmunity (Chur, Switzerland)
container_volume 36
creator Mix, Eilhard
Stefan, Katja
Höppner, Jaqueline
Klauer, Thomas
Zettl, Uwe K.
Strauss, Ulf
Meyer-Rienecker, Hans-J.
Rolfs, Arndt
description At present, the most efficient therapeutical treatment of multiple sclerosis (MS) is achieved by IFN- . However, its in vivo effects remain incompletely understood. If applied parenterally, the hydrophobic IFN- acts primarily on blood cells with probable selectivity for functionally different lymphocyte subpopulations, monocytes and granulocytes. We have investigated the expression of the activation marker interleukin-2 receptor- (CD25) on CD3+ T cells, CD19+ B cells, foetal-type +CD3+ T cells and foetal-type CD5+CD19+ B cells of the peripheral blood. In addition, the oxidative burst activity and apoptosis have been determined in mononuclear and polymorphonuclear blood cells, respectively. The study accompanied a phase III trial with IFN- 1b (BETAFERON®, Schering). Two groups of MS patients with relapsing-remitting course of the disease have been investigated at 8 time points (days 0, 5, 15, 31, 60, 90, 180 and 270 after starting therapy): (1) verum group (n=8) with application of 8 Mill. units IFN- 1b every other day, and (2) placebo group (n=4) with application of placebo for 3 months and therapy as in (1) from day 90 onward. The main results were: (1) Activated T cells decreased until day 180 in the verum group and return thereafter to pre-treatment values, whereas in the placebo group the values remained relatively stable over the whole observation period. (2) Activated B cells increased between days 90 and 270 in both groups, i.e. after verum application in both groups. (3) Foetal-type B cells were more activated than total B and T cells with increase over time in both groups. (4) Foetal-type T cells exerted relatively stable intra-individual levels with generally low CD25 expression, but punctual CD25 peaks in both groups. (5) The spontaneous oxidative burst was higher in lymphocytes, more variable in monocytes and faster increasing in granulocytes in the verum group than in the placebo group. (6) Apoptosis of mononuclear cells and granulocytes showed similar variations in the verum and placebo groups with the exception of a selective increase over time of the proportion of granulocytes undergoing induced apoptosis in the verum group. It is concluded that IFN- has the following main effects on the immune system of MS patients: (1) the T cell immunity is systemically and reversibly suppressed, (2) the foetal-type lymphocytes, which are responsible for the first line of defence of infections, are stimulated in the long range, (3) the oxidative burst ac
doi_str_mv 10.1080/0891693031000152697
format Article
fullrecord <record><control><sourceid>informahealthcare</sourceid><recordid>TN_cdi_informahealthcare_journals_10_1080_0891693031000152697</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>10_1080_0891693031000152697</sourcerecordid><originalsourceid>FETCH-informahealthcare_journals_10_1080_08916930310001526973</originalsourceid><addsrcrecordid>eNql0M1KxDAQB_AgCtaPJ_AyD2A1aWs_Dh7cZRcFxQU9eCuxnZAs2SQkqbrP4EubgkdvnmYYfn8G_oRcMHrFaEuvaduxuitpySil7Kaou-aAZKymTd5WxdshyWaRJ1Idk5MQtokVTV1l5Ptxv3PSDvuI8DK9O-smzaOyJlzC85ca0_6BsJh8iMDNCHdJRBtUAGVgg145iZ5rWGhrR1ii1gGsgE3KoYkBPlWU8DTpqJxOHwaNfk7nKyFwiDN9MBG9SGdzRo4E1wHPf-cpuV2vXpf3uTLC-h2XyHWUA_fYb-3kTTI9o_3cQP9HA-V_8z94RGrc</addsrcrecordid><sourcetype>Publisher</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Lymphocyte Subpopulations, Oxidative Burst and Apoptosis in Peripheral Blood Cells of Patients with Multiple Sclerosis-Effect of Interferon</title><source>Taylor &amp; Francis</source><creator>Mix, Eilhard ; Stefan, Katja ; Höppner, Jaqueline ; Klauer, Thomas ; Zettl, Uwe K. ; Strauss, Ulf ; Meyer-Rienecker, Hans-J. ; Rolfs, Arndt</creator><creatorcontrib>Mix, Eilhard ; Stefan, Katja ; Höppner, Jaqueline ; Klauer, Thomas ; Zettl, Uwe K. ; Strauss, Ulf ; Meyer-Rienecker, Hans-J. ; Rolfs, Arndt</creatorcontrib><description>At present, the most efficient therapeutical treatment of multiple sclerosis (MS) is achieved by IFN- . However, its in vivo effects remain incompletely understood. If applied parenterally, the hydrophobic IFN- acts primarily on blood cells with probable selectivity for functionally different lymphocyte subpopulations, monocytes and granulocytes. We have investigated the expression of the activation marker interleukin-2 receptor- (CD25) on CD3+ T cells, CD19+ B cells, foetal-type +CD3+ T cells and foetal-type CD5+CD19+ B cells of the peripheral blood. In addition, the oxidative burst activity and apoptosis have been determined in mononuclear and polymorphonuclear blood cells, respectively. The study accompanied a phase III trial with IFN- 1b (BETAFERON®, Schering). Two groups of MS patients with relapsing-remitting course of the disease have been investigated at 8 time points (days 0, 5, 15, 31, 60, 90, 180 and 270 after starting therapy): (1) verum group (n=8) with application of 8 Mill. units IFN- 1b every other day, and (2) placebo group (n=4) with application of placebo for 3 months and therapy as in (1) from day 90 onward. The main results were: (1) Activated T cells decreased until day 180 in the verum group and return thereafter to pre-treatment values, whereas in the placebo group the values remained relatively stable over the whole observation period. (2) Activated B cells increased between days 90 and 270 in both groups, i.e. after verum application in both groups. (3) Foetal-type B cells were more activated than total B and T cells with increase over time in both groups. (4) Foetal-type T cells exerted relatively stable intra-individual levels with generally low CD25 expression, but punctual CD25 peaks in both groups. (5) The spontaneous oxidative burst was higher in lymphocytes, more variable in monocytes and faster increasing in granulocytes in the verum group than in the placebo group. (6) Apoptosis of mononuclear cells and granulocytes showed similar variations in the verum and placebo groups with the exception of a selective increase over time of the proportion of granulocytes undergoing induced apoptosis in the verum group. It is concluded that IFN- has the following main effects on the immune system of MS patients: (1) the T cell immunity is systemically and reversibly suppressed, (2) the foetal-type lymphocytes, which are responsible for the first line of defence of infections, are stimulated in the long range, (3) the oxidative burst activity is increased in lymphocytes and granulocytes and instable in monocytes, and (4) the inducibility of apoptosis in granulocytes is increased. Re-examination of the altered blood cell parameters after long-term IFN- therapy is warranted.</description><identifier>ISSN: 0891-6934</identifier><identifier>EISSN: 1607-842X</identifier><identifier>DOI: 10.1080/0891693031000152697</identifier><language>eng</language><publisher>Informa UK Ltd</publisher><ispartof>Autoimmunity (Chur, Switzerland), 2003-08, Vol.36 (5), p.291-305</ispartof><rights>2003 Informa UK Ltd All rights reserved: reproduction in whole or part not permitted 2003</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.tandfonline.com/doi/pdf/10.1080/0891693031000152697$$EPDF$$P50$$Ginformahealthcare$$H</linktopdf><linktohtml>$$Uhttps://www.tandfonline.com/doi/full/10.1080/0891693031000152697$$EHTML$$P50$$Ginformahealthcare$$H</linktohtml><link.rule.ids>314,776,780,27901,27902,61194,61375</link.rule.ids></links><search><creatorcontrib>Mix, Eilhard</creatorcontrib><creatorcontrib>Stefan, Katja</creatorcontrib><creatorcontrib>Höppner, Jaqueline</creatorcontrib><creatorcontrib>Klauer, Thomas</creatorcontrib><creatorcontrib>Zettl, Uwe K.</creatorcontrib><creatorcontrib>Strauss, Ulf</creatorcontrib><creatorcontrib>Meyer-Rienecker, Hans-J.</creatorcontrib><creatorcontrib>Rolfs, Arndt</creatorcontrib><title>Lymphocyte Subpopulations, Oxidative Burst and Apoptosis in Peripheral Blood Cells of Patients with Multiple Sclerosis-Effect of Interferon</title><title>Autoimmunity (Chur, Switzerland)</title><description>At present, the most efficient therapeutical treatment of multiple sclerosis (MS) is achieved by IFN- . However, its in vivo effects remain incompletely understood. If applied parenterally, the hydrophobic IFN- acts primarily on blood cells with probable selectivity for functionally different lymphocyte subpopulations, monocytes and granulocytes. We have investigated the expression of the activation marker interleukin-2 receptor- (CD25) on CD3+ T cells, CD19+ B cells, foetal-type +CD3+ T cells and foetal-type CD5+CD19+ B cells of the peripheral blood. In addition, the oxidative burst activity and apoptosis have been determined in mononuclear and polymorphonuclear blood cells, respectively. The study accompanied a phase III trial with IFN- 1b (BETAFERON®, Schering). Two groups of MS patients with relapsing-remitting course of the disease have been investigated at 8 time points (days 0, 5, 15, 31, 60, 90, 180 and 270 after starting therapy): (1) verum group (n=8) with application of 8 Mill. units IFN- 1b every other day, and (2) placebo group (n=4) with application of placebo for 3 months and therapy as in (1) from day 90 onward. The main results were: (1) Activated T cells decreased until day 180 in the verum group and return thereafter to pre-treatment values, whereas in the placebo group the values remained relatively stable over the whole observation period. (2) Activated B cells increased between days 90 and 270 in both groups, i.e. after verum application in both groups. (3) Foetal-type B cells were more activated than total B and T cells with increase over time in both groups. (4) Foetal-type T cells exerted relatively stable intra-individual levels with generally low CD25 expression, but punctual CD25 peaks in both groups. (5) The spontaneous oxidative burst was higher in lymphocytes, more variable in monocytes and faster increasing in granulocytes in the verum group than in the placebo group. (6) Apoptosis of mononuclear cells and granulocytes showed similar variations in the verum and placebo groups with the exception of a selective increase over time of the proportion of granulocytes undergoing induced apoptosis in the verum group. It is concluded that IFN- has the following main effects on the immune system of MS patients: (1) the T cell immunity is systemically and reversibly suppressed, (2) the foetal-type lymphocytes, which are responsible for the first line of defence of infections, are stimulated in the long range, (3) the oxidative burst activity is increased in lymphocytes and granulocytes and instable in monocytes, and (4) the inducibility of apoptosis in granulocytes is increased. Re-examination of the altered blood cell parameters after long-term IFN- therapy is warranted.</description><issn>0891-6934</issn><issn>1607-842X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2003</creationdate><recordtype>article</recordtype><sourceid/><recordid>eNql0M1KxDAQB_AgCtaPJ_AyD2A1aWs_Dh7cZRcFxQU9eCuxnZAs2SQkqbrP4EubgkdvnmYYfn8G_oRcMHrFaEuvaduxuitpySil7Kaou-aAZKymTd5WxdshyWaRJ1Idk5MQtokVTV1l5Ptxv3PSDvuI8DK9O-smzaOyJlzC85ca0_6BsJh8iMDNCHdJRBtUAGVgg145iZ5rWGhrR1ii1gGsgE3KoYkBPlWU8DTpqJxOHwaNfk7nKyFwiDN9MBG9SGdzRo4E1wHPf-cpuV2vXpf3uTLC-h2XyHWUA_fYb-3kTTI9o_3cQP9HA-V_8z94RGrc</recordid><startdate>200308</startdate><enddate>200308</enddate><creator>Mix, Eilhard</creator><creator>Stefan, Katja</creator><creator>Höppner, Jaqueline</creator><creator>Klauer, Thomas</creator><creator>Zettl, Uwe K.</creator><creator>Strauss, Ulf</creator><creator>Meyer-Rienecker, Hans-J.</creator><creator>Rolfs, Arndt</creator><general>Informa UK Ltd</general><scope/></search><sort><creationdate>200308</creationdate><title>Lymphocyte Subpopulations, Oxidative Burst and Apoptosis in Peripheral Blood Cells of Patients with Multiple Sclerosis-Effect of Interferon</title><author>Mix, Eilhard ; Stefan, Katja ; Höppner, Jaqueline ; Klauer, Thomas ; Zettl, Uwe K. ; Strauss, Ulf ; Meyer-Rienecker, Hans-J. ; Rolfs, Arndt</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-informahealthcare_journals_10_1080_08916930310001526973</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2003</creationdate><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Mix, Eilhard</creatorcontrib><creatorcontrib>Stefan, Katja</creatorcontrib><creatorcontrib>Höppner, Jaqueline</creatorcontrib><creatorcontrib>Klauer, Thomas</creatorcontrib><creatorcontrib>Zettl, Uwe K.</creatorcontrib><creatorcontrib>Strauss, Ulf</creatorcontrib><creatorcontrib>Meyer-Rienecker, Hans-J.</creatorcontrib><creatorcontrib>Rolfs, Arndt</creatorcontrib><jtitle>Autoimmunity (Chur, Switzerland)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Mix, Eilhard</au><au>Stefan, Katja</au><au>Höppner, Jaqueline</au><au>Klauer, Thomas</au><au>Zettl, Uwe K.</au><au>Strauss, Ulf</au><au>Meyer-Rienecker, Hans-J.</au><au>Rolfs, Arndt</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Lymphocyte Subpopulations, Oxidative Burst and Apoptosis in Peripheral Blood Cells of Patients with Multiple Sclerosis-Effect of Interferon</atitle><jtitle>Autoimmunity (Chur, Switzerland)</jtitle><date>2003-08</date><risdate>2003</risdate><volume>36</volume><issue>5</issue><spage>291</spage><epage>305</epage><pages>291-305</pages><issn>0891-6934</issn><eissn>1607-842X</eissn><abstract>At present, the most efficient therapeutical treatment of multiple sclerosis (MS) is achieved by IFN- . However, its in vivo effects remain incompletely understood. If applied parenterally, the hydrophobic IFN- acts primarily on blood cells with probable selectivity for functionally different lymphocyte subpopulations, monocytes and granulocytes. We have investigated the expression of the activation marker interleukin-2 receptor- (CD25) on CD3+ T cells, CD19+ B cells, foetal-type +CD3+ T cells and foetal-type CD5+CD19+ B cells of the peripheral blood. In addition, the oxidative burst activity and apoptosis have been determined in mononuclear and polymorphonuclear blood cells, respectively. The study accompanied a phase III trial with IFN- 1b (BETAFERON®, Schering). Two groups of MS patients with relapsing-remitting course of the disease have been investigated at 8 time points (days 0, 5, 15, 31, 60, 90, 180 and 270 after starting therapy): (1) verum group (n=8) with application of 8 Mill. units IFN- 1b every other day, and (2) placebo group (n=4) with application of placebo for 3 months and therapy as in (1) from day 90 onward. The main results were: (1) Activated T cells decreased until day 180 in the verum group and return thereafter to pre-treatment values, whereas in the placebo group the values remained relatively stable over the whole observation period. (2) Activated B cells increased between days 90 and 270 in both groups, i.e. after verum application in both groups. (3) Foetal-type B cells were more activated than total B and T cells with increase over time in both groups. (4) Foetal-type T cells exerted relatively stable intra-individual levels with generally low CD25 expression, but punctual CD25 peaks in both groups. (5) The spontaneous oxidative burst was higher in lymphocytes, more variable in monocytes and faster increasing in granulocytes in the verum group than in the placebo group. (6) Apoptosis of mononuclear cells and granulocytes showed similar variations in the verum and placebo groups with the exception of a selective increase over time of the proportion of granulocytes undergoing induced apoptosis in the verum group. It is concluded that IFN- has the following main effects on the immune system of MS patients: (1) the T cell immunity is systemically and reversibly suppressed, (2) the foetal-type lymphocytes, which are responsible for the first line of defence of infections, are stimulated in the long range, (3) the oxidative burst activity is increased in lymphocytes and granulocytes and instable in monocytes, and (4) the inducibility of apoptosis in granulocytes is increased. Re-examination of the altered blood cell parameters after long-term IFN- therapy is warranted.</abstract><pub>Informa UK Ltd</pub><doi>10.1080/0891693031000152697</doi></addata></record>
fulltext fulltext
identifier ISSN: 0891-6934
ispartof Autoimmunity (Chur, Switzerland), 2003-08, Vol.36 (5), p.291-305
issn 0891-6934
1607-842X
language eng
recordid cdi_informahealthcare_journals_10_1080_0891693031000152697
source Taylor & Francis
title Lymphocyte Subpopulations, Oxidative Burst and Apoptosis in Peripheral Blood Cells of Patients with Multiple Sclerosis-Effect of Interferon
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-08T06%3A13%3A29IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-informahealthcare&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Lymphocyte%20Subpopulations,%20Oxidative%20Burst%20and%20Apoptosis%20in%20Peripheral%20Blood%20Cells%20of%20Patients%20with%20Multiple%20Sclerosis-Effect%20of%20Interferon&rft.jtitle=Autoimmunity%20(Chur,%20Switzerland)&rft.au=Mix,%20Eilhard&rft.date=2003-08&rft.volume=36&rft.issue=5&rft.spage=291&rft.epage=305&rft.pages=291-305&rft.issn=0891-6934&rft.eissn=1607-842X&rft_id=info:doi/10.1080/0891693031000152697&rft_dat=%3Cinformahealthcare%3E10_1080_0891693031000152697%3C/informahealthcare%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/&rfr_iscdi=true